Molbio Diagnostics Seeks IPO to Fuel Global Expansion Amid Tuberculosis Test Success

Molbio Diagnostics, a company known for its molecular diagnostics, is preparing to launch an initial public offering (IPO) aiming to raise ₹940 crore. The company plans to secure ₹200 crore through a fresh issue of shares to support capital expenditures, while an additional ₹740 crore is anticipated from an offer for sale, which will reduce the promoter group's stake from 46.6% to 43%.

Global Reach and Product Focus

Established in 2000, Molbio Diagnostics has grown its operations significantly, now running six manufacturing facilities across India. The company serves clients in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A significant portion of its revenue is concentrated among its top clients, which may present a risk factor for potential investors.

The company is widely recognized for its 'Truenat' platform, a portable diagnostics system especially designed for resource-limited settings. This platform provides accurate test results in less than an hour and supports molecular testing for over 30 diseases through 43 diagnostic assays. Significantly, nearly 74% of Molbio's revenue is derived from the sale of test kits, with tuberculosis kits accounting for 70% of this figure.

Financial Performance and Market Position

Molbio Diagnostics has demonstrated robust financial growth over the past few years. Between FY24 and FY26, its revenue from operations increased by 31.5% annually, reaching ₹1,445.7 crore. During the same period, net profit saw a 40.2% annual growth, amounting to ₹164.1 crore. The company's operating profit before interest, tax, depreciation, and amortization (EBITDA) rose by 33.2% to ₹328.2 crore, with the EBITDA margin improving from 22% in FY24 to 22.6% in FY26.

In FY26 alone, Molbio's revenue jumped by 41.7% year-on-year, while EBITDA rose by 27.9% and net profit increased by 18.4%. The post-IPO valuation demands a price-earnings (P/E) multiple of up to 57. Although Molbio has no directly comparable listed peer in India, other companies in the healthcare diagnostics and medical devices sector, such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, trade at P/E multiples ranging from 54 to 81.

Investment Considerations

Molbio Diagnostics' IPO presents an opportunity for investors with a high-risk appetite seeking long-term growth. The company's stronghold in the tuberculosis diagnostics market, coupled with its expanding global footprint, positions it as a potential growth driver in the molecular diagnostics sector. However, investors should consider the risks associated with customer concentration and the competitive landscape of the healthcare diagnostics industry.